Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273602 | 0.91 | PLG (0.49) | PLAUPLGCCR2PLA2G10HTT | |
| SCHEMBL6193094 | 0.88 | PLA2G10 (0.57) | PLAUPLGGLO1CCR2PLA2G10 | |
| SCHEMBL27580834 | 0.86 | PLAU (0.56) | PLAUPLGGLO1CCR2PLA2G10 | |
| SCHEMBL2280081 | 0.86 | GLO1 (0.59) | PLAUPLGGLO1CCR2PLA2G10 | |
| SCHEMBL2277407 | 0.82 | HDAC8 (0.61) | NR1H4PPARGHDAC1HDAC2HDAC10 | |
| SCHEMBL30888879 | 0.82 | PLAU (0.57) | PLAUPLGPPARGHDAC1HDAC2 | |
| SCHEMBL15971036 | 0.82 | PLAU (0.57) | PLAUPLGPPARGHDAC1HDAC2 | |
| SCHEMBL3506074 | 0.82 | PLG (0.52) | PLAUPLGGLO1CCR2PPARG | |
| SCHEMBL3674159 | 0.81 | MRGPRX4 (0.62) | NR1H4BCL2MCL1 | |
| SCHEMBL30185512 | 0.81 | PLAU (0.56) | PLAUPLGNR1H4PPARGHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | claimed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | claimed |
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | FLI1, API5, MAVS | PLAU 4157/4885PLG 2799/4885GLO1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.